Swiss drugmaker Novartis has announced to discontinue Hydroxychloroquine (HCQ) clinical trial over acute enrollment challenges that have made completion of the trial infeasible, and not because any safety issues were reported or efficacy conclusions made.
The Competition Commission of India has initiated probe against four drugmakers for alleged price fixing of a popular anti-diabetic drug.
New Delhi, May 10: Drug major Novartis India has said its Swiss promoter Novartis AG has appointed Citigroup Capital Markets as the broker for the proposed share sale to reduce stake in the Indian entity."Novartis
New Delhi, April 2: The Supreme Court's rejection of Novartis's patent plea for cancer drug 'Glivec' was hailed by domestic pharma companies as a "landmark' verdict that will help the poor have easier access to
Top News
Latest News
